Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy
Swetha Kambhampati(Johns Hopkins University), Sandy W. Wong(UCSF Helen Diller Family Comprehensive Cancer Center), Weiyun Z. Ai(City College of San Francisco), Nina Shah(The University of Texas MD Anderson Cancer Center), Sophia Byslma(University of California, San Francisco), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Ying Sheng(University of California, San Francisco), Charalambos Andreadis(University of California, San Francisco), Chiung‐Yu Huang, Dhruba Biswas(University of California, San Francisco), Thomas Martin(University of California, San Francisco), Bita Fakhri(University of California, San Francisco), Jeffrey L. Wolf(City College of San Francisco), Mimi Lo(University of California, San Francisco), Kelsey Natsuhara(University of California, San Francisco)
Cited by 12
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523